The future of Nippon Shinyaku’s Duchenne muscular dystrophy (DMD) therapy Viltepso has been thrown into doubt after it failed a clinical trial designed to upgrade its 2020 accelerated approval.

Click the link below to download a spreadsheet with an example Beta (5 Year) calculation for Nippon Shinyaku Co Ltd ADR below: The chart above depicts the distribution of Beta (5 Year) for ...

NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku), announced today that acceptance has been received by Capricor Therapeutics, Inc. (Headquarters: California, ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

ROCKVILLE, Md. - REGENXBIO Inc. (NASDAQ:RGNX), a biotechnology company currently valued at $293 million, has completed a strategic partnership with Japanese pharmaceutical firm Nippon Shinyaku to ...

Regenxbio (RGNX) announced the closing of its previously announced strategic partnership with Nippon Shinyaku. Under the terms of the ...

Regenxbio closes strategic partnership with Nippon Shinyaku for MPS diseases: Rockville, Maryland Wednesday, March 5, 2025, 14:00 Hrs [IST] Regenxbio Inc., a leading clinical-stag ...

Reports Q4 revenue $21.2M, consensus $23.7M. Expects its balance in cash, cash equivalents and marketable securities of $244.9M as of December ...

REGENXBIO Inc. (Nasdaq: RGNX) today announced the closing of its previously announced strategic partnership with Nippon Shinyaku.

We've identified the following companies as similar to Nippon Shinyaku Co Ltd ADR because they operate in a related industry or sector. We also considered size, growth, and various financial metrics ...